About Us - Drug Development Technology

Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Advertise with us

APIs

Vaccine development: the need for speed

Lack of CMO availability threatens cell and gene therapy development

Novaliq’s NovaTears+Omega-3 represents the first-in-class omega-3-containing eye drop for evaporative dry eye

Approvals

Will the UK relax its current regulations for cannabis-based products?

CAR-T toxicity rating system to be finalized by ASBMT by year-end

August’s top news stories

Clinical Research

Will the UK relax its current regulations for cannabis-based products?

Could Bristol-Myers Squibb change the psoriasis market?

The UK is home to the world leader in plant-derived cannabinoid therapeutics

Clinical Trials

Ovid Therapeutics starts ELEKTRA and ARCADE trials for rare epilepsies

Galapagos doses first patient in Phase ll trial of GLPG1972/S201086

AstraZeneca reports positive data from type 2 diabetes Phase III trial

Diseases

Could Bristol-Myers Squibb change the psoriasis market?

Gilead and Galapagos AS drug meets primary endpoint

Phase I study tests imiquimod cream for immune response to influenza

Genomics & Proteomics

August’s top news stories

July’s top news stories

June’s top news stories

Market Data

Deals and M&As this week: CRISPR, Integral Molecular, Evotec

Will the UK relax its current regulations for cannabis-based products?

Deals this week: Zealand Pharma, Fulcrum Therapeutics, Forendo Pharma

Technology

August’s top news stories

July’s top news stories

Genentech doses first patient in Perjeta and Herceptin Phase 3 study

Online

Read more

In Print

Read more